Search Results - "CHERRINGTON, Julie M"

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer by Abrams, Tinya J, Lee, Leslie B, Murray, Lesley J, Pryer, Nancy K, Cherrington, Julie M

“…The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine kinase KIT in vitro and in vivo…”
Get full text

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer by Abrams, Tinya J, Murray, Lesley J, Pesenti, Enrico, Holway, Vicky Walker, Colombo, Tina, Lee, Leslie B, Cherrington, Julie M, Pryer, Nancy K

“…SU11248 is an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities through targeting platelet-derived growth factor…”
Get full text

An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients by O'FARRELL, Anne-Marie, FORAN, James M, HEINRICH, Michael C, BERDEL, Wolfgang E, BELLO, Carlo, JACOBS, Mark, SCIGALLA, Paul, MANNING, William C, KELSEY, Stephen, CHERRINGTON, Julie M, FIEDLER, Walter, SERVE, Hubert, PAQUETTE, Ron L, COOPER, Maureen A, YUEN, Helene A, LOUIE, Sharianne G, KIM, Heidi, NICHOLAS, Susan

“…Purpose: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted…”
Get full text

Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies by LONDON, Cheryl A, HANNAH, Alison L, MENDEL, Dirk B, MCMAHON, Gerald, CHERRINGTON, Julie M, ZADOVOSKAYA, Regina, CHIEN, May B, KOLLIAS-BAKER, Cynthia, ROSENBERG, Mona, DOWNING, Sue, POST, Gerald, BOUCHER, Joseph, SHENOY, Narmada

“…Purpose : The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone receptor tyrosine kinase (RTK)…”
Get full text

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 by Potapova, Olga, Laird, A Douglas, Nannini, Michelle A, Barone, Angela, Li, Guangmin, Moss, Katherine G, Cherrington, Julie M, Mendel, Dirk B

“…Recent achievements in the development of multitargeted molecular inhibitors necessitate a better understanding of the contribution of activity against…”
Get full text

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity by Patyna, Shem, Laird, A Douglas, Mendel, Dirk B, O'farrell, Anne-Marie, Liang, Chris, Guan, Huiping, Vojkovsky, Tomas, Vasile, Stefan, Wang, Xueyan, Chen, Jeffrey, Grazzini, Maren, Yang, Cheng Y, Haznedar, Joshua O, Sukbuntherng, Juthamas, Zhong, Wei-Zhu, Cherrington, Julie M, Hu-Lowe, Dana

“…Receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor…”
Get full text

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model by Murray, Lesley J, Abrams, Tinya J, Long, Kelly R, Ngai, Theresa J, Olson, Lisa M, Hong, Weiru, Keast, Paul K, Brassard, Jacqueline A, O'Farrell, Anne Marie, Cherrington, Julie M, Pryer, Nancy K

“…The aim of the study was to investigate inhibitory effects of the receptor tyrosine kinase (RTK) inhibitor SU11248 against CSF-1R and osteoclast (OC)…”
Get full text

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase by Yee, Kevin W.H., O'Farrell, Anne Marie, Smolich, Beverly D., Cherrington, Julie M., McMahon, Gerald, Wait, Cecily L., McGreevey, Laura S., Griffith, Diana J., Heinrich, Michael C.

“…Internal tandem duplication (ITD) in the juxtamembrane portion of Fms-like tyrosine kinase 3 (FLT3), a type III receptor tyrosine kinase (RTK), is the most…”
Get full text

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents by Laird, A Douglas, Cherrington, Julie M

“…Numerous small molecule synthetic tyrosine kinase inhibitors are in clinical development for the treatment of human cancers. These fall into three broad…”
Get more information

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts by Smolich, Beverly D., Yuen, Helene A., West, Kristina A., Giles, Francis J., Albitar, Maher, Cherrington, Julie M.

“…SU5416 and SU6668 are potent antiangiogenic small-molecule inhibitors of receptor tyrosine kinases, including those of the vascular endothelial growth factor…”
Get full text

The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation by Ning, Shoucheng, Laird, Douglas, Cherrington, Julie M., Knox, Susan J.

“…Ning, S., Laird, D., Cherrington, J. M. and Knox, S. J. The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation…”
Get full text

The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function by MENDEL, Dirk B, SCHRECK, Randall E, WEST, David C, GUANGMIN LI, STRAWN, Laurie M, TANCIONGCO, Sheila S, VASILE, Stefan, SHAWVER, Laura K, CHERRINGTON, Julie M

“…SU5416, a selective inhibitor of the tyrosine kinase activity of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR, is currently in Phase III…”
Get full text

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors by Liao, Albert T., Chien, May B., Shenoy, Narmada, Mendel, Dirk B., McMahon, Gerald, Cherrington, Julie M., London, Cheryl A.

“…Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the negative regulatory juxtamembrane (JM) domain or point…”
Get full text

Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans by Moss, Katherine G, Toner, Guy C, Cherrington, Julie M, Mendel, Dirk B, Laird, A Douglas

“…Deregulated activation of the KIT receptor tyrosine kinase has been implicated in several human cancers and in inflammation, making it an attractive target for…”
Get more information

New paradigms for the treatment of cancer: The role of anti-angiogenesis agents by Cherrington, Julie M., Strawn, Laurie M., Shawver, Laura K.

“…Angiogenesis, the sprouting of new blood vessels, plays a role in diverse disease states including cancer, diabetic retinopathy, age-related macular…”
Get full text

High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes by Smith, Irene L., Cherrington, Julie M., Jiles, Rhett E., Fuller, Michael D., Freeman, William R., Spector, Stephen A.

“…Mutations in both the viral phosphotransferase gene, UL97, and the DNA polymerase gene, UL54, have been shown to confer ganciclovir resistance to…”
Get full text

The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically by GAROFALO, Angela, NAUMOVA, Elitza, GIAVAZZI, Raffaella, MANENTI, Luigi, GHILARDI, Carmen, GHISLENI, Gabriele, CANIATTI, Mario, COLOMBO, Tina, CHERRINGTON, Julie M, SCANZIANI, Eugenio, NICOLETTI, Maria Ines

“…Purpose: The purpose of this study was to investigate the antitumor activity of SU6668, tyrosine kinase inhibitor of vascular endothelial growth factor…”
Get full text

Human Immunodeficiency Virus Type 1 Expressing the Lamivudine-Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In Vitro by Miller, Michael D., Anton, Kristin E., Mulato, Andrew S., Lamy, Patrick D., Cherrington, Julie M.

“…In a phase II study of 6–12 months of adefovir dipivoxil treatment in human immunodeficiency virus (HIV)-infected patients, HIV from 8 of 29 patients developed…”
Get full text

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification by DePrimo, Samuel E, Wong, Lily M, Khatry, Deepak B, Nicholas, Susan L, Manning, William C, Smolich, Beverly D, O'Farrell, Anne-Marie, Cherrington, Julie M

“…Microarray-based gene expression profiling is a powerful approach for the identification of molecular biomarkers of disease, particularly in human cancers…”
Get full text

Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects by O'Farrell, A. Marie, PhD, van Vliet, Andre, MD,PhD, Abou Farha, Khalid, MD,PhD, Cherrington, Julie M., PhD, Campbell, David A., PhD, Li, Xinqiang, PhD, Hanway, Denise, MS, Li, Jianke, PhD, Guler, Hans-Peter, MD

“…Abstract Background: PHX1149 is a dipeptidyl peptidase-4 (DPP4) inhibitor that is currently in clinical development for the treatment of type 2 diabetes…”
Get full text